Ptc Therapeutics (PTCT) Depreciation and Depletion (2012 - 2020)

Ptc Therapeutics' Depreciation and Depletion history runs 9 years deep, the most recent figure standing at -$24.5 million for Q4 2020.

• On a quarterly basis, Depreciation and Depletion fell 34.53% year-over-year to -$24.5 million in Q4 2020; TTM through Dec 2020 was $6.6 million, a 40.43% increase from a year earlier, with the FY2024 full-year figure at $14.9 million, up 7.19% from the prior year.
• Depreciation and Depletion eased to -$24.5 million in Q4 2020 per PTCT's latest filing, from $11.6 million in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $11.6 million in Q3 2020 and bottomed at -$24.5 million in Q4 2020.
• The 5-year median for Depreciation and Depletion is $3.4 million (2016), against an average of $975000.0.
• Biggest YoY gain for Depreciation and Depletion was 1166.3% in 2017; the steepest drop was 1247.39% in 2017.
• Year by year, Depreciation and Depletion stood at $823000.0 in 2016, then plunged by 1247.39% to -$9.4 million in 2017, then plunged by 77.02% to -$16.7 million in 2018, then fell by 8.9% to -$18.2 million in 2019, then sank by 34.53% to -$24.5 million in 2020.
• Per Business Quant, the three latest PTCT Depreciation and Depletion figures stand at -$24.5 million (Q4 2020), $11.6 million (Q3 2020), and $10.2 million (Q2 2020).